Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

NCT05758493 is registered in ClinicalTrials.gov with Oregon Health and Science University as lead sponsor.

NCT NCT05758493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05758493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Lead sponsor
Oregon Health and Science University
Phase
Phase 2
Overall status
Recruiting
Start date
January 10, 2023
Completion date
March 10, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, transthyretin amyloidosis